48 results about "Cd4 t cell" patented technology

The present invention relates to chimeric molecules that comprise human major histocompatibility complex elements, linked to epitopes of interest, that have been joined together to form dimers or higher multimers. Such chimeric molecules may be used to treat or prevent diseases associated with autoimmunity, particularly diabetes. It is based, at least in part, on the discovery that a chimeric molecule comprising an IILA-DR element linked to an epitope of GAD65, an antigen associated with autoimmune diabetes, stimulated the secretion of the inhibitory cytokine IL-10 from CD4 T cells of Type I diabetic patients.

The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods relate to in vivo and ex vivo enrichment of HIV-specific CD4 T cells. In certain embodiments, the disclosed compositions and methods can incorporate therapy in order to further enhance the HIV-specific CD4 T cells.

The invention provides methods of identifying naïve T cells by expression of PTK7.

The invention relates to a multi-subtype influenza virus HA2 protein common epitope, an antibody, an identification method and application. The antigen epitope can be combined with immune serum of H1,H3, H4, H5, H6, H7, H8, H9 and H10 subtype influenza viruses. The method comprises the following steps: selecting an H5N1 subtype influenza virus strain S, designing 18 polypeptides with the length of 20 amino acids and overlapped 10 amino acids according to the sequence of the HA2 protein of the H5N1 subtype influenza virus strain S, artificially synthesizing, spotting to a modified silica gel film to prepare a polypeptide chip, and screening universal epitopes by using antiserum aiming at different subtype IAVs. The recombinant virus with the mutated epitope is constructed, and the bindingcapacity of the epitope and immune serum is analyzed through western blot. Results show that 485-FYHKCDNECME-495 on the HA2 protein has broad-spectrum binding activity with H1, H3, H4, H5, H6, H7, H8,H9 and H10 subtype IAV antiserum. K / D mutation in the recombinant virus leads to reduction of the serum binding activity, which indicates that the K / D mutation is a key amino acid of the serum binding activity. The peptide fragment also comprises an HLA-DR1 (Human Leukocyte Antigen-DR1) restrictive CD4 T cell epitope.

The present invention relates to recombinant acetylcholine receptor polypeptides recognized by CD4 T cells of a myasthenia gravis patient and compositions for the treatment of myasthenia gravis containing the same as an effective ingredient, more precisely, recombinant acetylcholine receptor polypeptides deficient in B cell epitope, recombinant acetylcholine polypeptides in which two or more T cell epitopes are fused, a composition for the treatment of myasthenia gravis containing the above recombinant polypeptides as an effective ingredient and a treatment method for myasthenia gravis using the composition. The composition containing one or more recombinant polypeptides above can be effectively used as a myasthenia gravis specific therapeutic agent or immunomodulator without side effects.

The invention discloses a plutella xylostella antibacterial peptide as well as applications thereof to preparation of anti-infective drugs, antitumor drugs, immunopotentiators and feed additives. An amino acid sequence of the plutella xylostella antibacterial peptide is represented by SEQ ID No.3. The plutella xylostella antibacterial peptide has inhibition and killing effects on various bacteria, so that the peptide can be used for preparing the anti-infective drugs; the plutella xylostella antibacterial peptide has the extremely significant growth inhibition effect on breast cancer cells, hepatoma cells, colonic cancer cells and lung cancer cells and has the obvious antitumor activity in vitro, so that the peptide can be used for preparing the antitumor drugs; the plutella xylostella antibacterial peptide can promote CD4T cells to proliferate and secrete IFNgamma, can inhibit synthesis of IL4 and regulate balance of Th1 / Th2 and has the immunological enhancement activity, so that the peptide can be used for preparing the immunopotentiators; the plutella xylostella antibacterial peptide can significantly increase the survival rate of piglets, reduce the diarrhea rate of the piglets and growing and fattening pigs, increase the daily gain of the piglets and the growing and fattening pigs and reduce the feed conversion ratio of the piglets and the growing and fattening pigs when being used as the feed additives.

Cytotoxic T lymphocytes (CTLs) specific for antigenic peptides derived from IgE molecule can be generated in vitro by stimulating resting naive CD8 T cells with IgE peptides presented by artificial antigen presenting cells. The IgE specific CTLs lyse the target cells loaded with IgE peptides in vitro and inhibit antigen specific IgE response in vivo. In addition, adoptive transfer of the IgE specific CTL to an asthmatic mouse model can inhibit the development of lung inflammation and airway hypersensitivity. IgE specific CTL provides a treatment for allergic asthma and other IgE-mediated allergic diseases. Antigenic peptides identified from non-tumor self-antigens induce specific cytotoxic T lymphocyte (CTL) in vitro. The CTL induced by peptides identified from CD40L can kill activated CD4 T cells. In vitro generated CTL specific for CD40L inhibit CD4-dependent antibody responses of all isotypes in vivo. In contrast, CTL induced by antigenic peptides derived from IgE specifically inhibit IgE responses, and adoptive transfer of CD40L-specific CTL to NOD mice at early age delay the development of diabetes in NOD mice. In vitro generated CTL specific for non-tumor self-antigens expressed on activated CD4 T cells regulate immune responses in vivo.

The invention discloses a DN T cell transformation and multiplication method which comprises the following steps: (1) extracting mononuclear cells in an initial sample, and removing CD8<+>T cells and NK cells from the mononuclear cells; (2) culturing the sample obtained in the step (1) in vitro with a culture medium containing a T cell stimulant and cell factors; adding an OX40 activated antibody or an OX40 ligand at the same time in the culturing process; (3) purifying DN T cells after 5-7 days' culture. The method can be implemented without purifying CD4<+>T cells or natural DN T cells, so that the operation difficulty is reduced, the operation efficiency is improved, and the culture period is short; the apoptosis rate of DN T cells in multiplication can be effectively reduced, and the immunosuppression function can be improved; the DN T cell yield is greatly improved as compared with that in the prior art; the obtained DN T cells have remarkable immunosuppression function, the percentage of the proliferated CD4 T cells is reduced to 2.94% as compared with that in the prior art, and the suppression ratio can reach 93%.

The present invention relates to a polynucleotide encoding CDR3 in the TCR-α chain and TCR-β chain genes of CD4+ helper T cells specific for a WT1 helper peptide having the amino acid sequence of SEQ ID NO: 123 . The invention also relates to the peptides encoded by said polynucleotides. The present invention also relates to CD4+T cells into which the TCR gene containing the polynucleotide has been introduced, the use of CD4+T cells to induce WT1-specific cytotoxic T-lymphocytes (CTL), cancer treatment, and the like.